Skip to main content

Table 2 Patient characteristics

From: Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study

 

High volume hydration Mg-

High volume hydration Mg+

Low volume hydration Mg+

 

(n = 41)

(n = 27)

(n = 17)

Age (year)

66 (63 to 70)

66 (57 to 70)

63 (62 to 67)

Gender Male (%)

31 (75.6)

18 (66.6)

16 (94.1)

BSA (m2)

1.7 ± 0.2

1.6 ± 0.2

1.7 ± 0.2

PS (ECOG): 0 (%)

5 (12.1)

4 (14.8)

5 (29.4)

    1 (%)

36 (87.8)

23 (85.2)

12 (70.6)

Stage  I (%)

0 (0)

1 (3.7)

0 (0)

    II (%)

5 (12.2)

3 (11.1)

3 (17.6)

    III (%)

25 (61.0)

15 (55.5)

8 (47.1)

    IV (%)

9 (22.0)

7 (25.9)

6 (35.3)

 Others (%)

2 (4.9)

1 (3.7)

0 (0)

Histology Adenocarcinoma (%)

17 (41.5)

13 (48.1)

11 (64.7)

    Squamous cell carcinoma (%)

11 (26.8)

7 (25.9)

5 (29.4)

    Small cell carcinoma (%)

9 (22.0)

6 (22.2)

1 (5.9)

    Others (%)

4 (9.8)

1 (3.7)

0 (0)

Serum Hb (g/dl)

13.3 (12.0 to 14.8)

13.6 (12.8 to 14.8)

13.3 (12.7 to 14.9)

Serum Alb (g/dl)

4.0 ± 0.4

4.1 ± 0.4

3.9 ± 0.4

Cisplatin dose (mg/m2)

80 (80 to 80)

80 (75 to 80)

80 (75 to 80)

Regular use drug

   

NSAIDs (%)

10 (24.4)

2 (7.4)

2 (11.7)

Mg for purgative (%)

14 (34.1)

8 (29.6)

5 (29.4)

Combined anticancer agent (%)

   

  VNB

22 (53.7)

13 (48.1)

10 (58.8)

  PEM

3 (7.3)

6 (22.2)

5 (29.4)

  CPT-11

3 (7.4)

1 (3.7)

0

  VP-16

8 (19.5)

6 (22.2)

1 (5.9)

  GEM

2 (4.9)

0

1 (5.9)

  S-1

1 (2.4)

1 (3.7)

0

  AMR

1 (2.4)

0

0

  DTX

1 (2.4)

0

0

  1. Continuous variables are expressed as mean ± standard deviation or median (interquartile range). Categorical variables are expressed as number (proportion).
  2. BSA, body surface area; PS, performance status; Hb, hemogulobin; Alb, albumin; NSAIDs, non-steroid anti-Inflammatory drugs; Non-Steroidal Anti-Inflammatory Drugs; Mg for purgative, Mg-contating medications for purgative; VNB, vinorelbine; PEM, pemetrexed; CPT-11, irinotecan; VP-16, etoposide; GEM, gemcitabine; AMR, amurubicin; DTX, docetaxel.